Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5 Formyltetrahydrofolate
2. 5 Formyltetrahydropteroylglutamate
3. 5-formyltetrahydrofolate
4. 5-formyltetrahydropteroylglutamate
5. Acid, Folinic
6. Calcium Folinate
7. Citrovorum Factor
8. Factor, Citrovorum
9. Folinate, Calcium
10. Folinic Acid
11. Folinic Acid Sf
12. Folinic Acid-sf
13. Leucovorin
14. Leucovorin, (d)-isomer
15. Leucovorin, (dl)-isomer
16. Leucovorin, (r)-isomer
17. Leucovorin, Calcium
18. Leucovorin, Calcium (1:1) Salt
19. Leucovorin, Calcium (1:1) Salt, (dl)-isomer
20. Leucovorin, Calcium (1:1) Salt, Pentahydrate
21. Leucovorin, Monosodium Salt
22. Leukovorin
23. Leukovorum
24. Monosodium Salt Leucovorin
25. N(5)-formyltetrahydrofolate
26. Wellcovorin
1. Calcium Folinate
2. Calcium Citrovorum Factor
3. Folinic Acid Calcium Salt
4. Folinic Acid-sf, Calcium Salt
5. (+)-l-folinic Acid, Calcium Salt
6. 1492-18-8
7. Nsc3590
8. Sr-05000001662
9. Pharmakon1600-01500364
10. Nsc757083
11. Nsc-757083
12. Sr-05000001662-1
13. Sr-05000001662-2
14. Glutamic Acid,6,7,8-tetrahydro-4-hydroxy-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), L-
15. L-glutamic Acid,4,5,6,7,8-hexahydro-4-oxo-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), (s)-
Molecular Weight | 513.5 g/mol |
---|---|
Molecular Formula | C20H23CaN7O7+2 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 9 |
Exact Mass | 513.1284869 g/mol |
Monoisotopic Mass | 513.1284869 g/mol |
Topological Polar Surface Area | 216 Ų |
Heavy Atom Count | 35 |
Formal Charge | 2 |
Complexity | 911 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
Vitamin B Complex
A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AF - Detoxifying agents for antineoplastic treatment
V03AF03 - Calcium folinate
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25334
Submission : 2011-08-09
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-04
Pay. Date : 2013-09-25
DMF Number : 5046
Submission : 1983-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16718
Submission : 2003-07-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-08-16
Pay. Date : 2019-06-24
DMF Number : 33740
Submission : 2019-05-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-07-26
Pay. Date : 2024-06-10
DMF Number : 38878
Submission : 2023-09-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-03-02
Pay. Date : 2018-02-20
DMF Number : 5261
Submission : 1984-01-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-10-18
Pay. Date : 2024-09-19
DMF Number : 40427
Submission : 2024-09-04
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10232
Submission : 1993-03-06
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5429
Submission : 1984-07-09
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3715
Submission : 1980-02-11
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody, which is currently being evaluated for early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Lead Product(s): Durvalumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2025
Lead Product(s) : Durvalumab,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imfinzi based Regimen Shows Significant Event-Free Survival Benefit in Gastric Cancers
Details : Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody, which is currently being evaluated for early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Product Name : Imfinzi
Product Type : Antibody
Upfront Cash : Inapplicable
March 07, 2025
Details:
ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9. It is being evaluated for the treatment of familial adenomatous polyposis.
Lead Product(s): ST316,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2024
Lead Product(s) : ST316,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sapience Receives FDA Orphan Drug Designation for ST316 in Familial Adenomatous Polyposis
Details : ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9. It is being evaluated for the treatment of familial adenomatous polyposis.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Not Applicable
December 19, 2024
Details:
CEND-1 (certepetide) is an Alpha-V integrin inhibitor peptide candidiate which is being evaluated in combination with chemotherapy for the treatment of pancreatic cancer.
Lead Product(s): Calcium Folinate,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2024
Lead Product(s) : Calcium Folinate,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Details : CEND-1 (certepetide) is an Alpha-V integrin inhibitor peptide candidiate which is being evaluated in combination with chemotherapy for the treatment of pancreatic cancer.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Not Applicable
December 10, 2024
Details:
ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9. It is being evaluated for the treatment of colorectal cancer.
Lead Product(s): ST316,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Brand Name: ST316
Study Phase: Phase I/ Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2024
Lead Product(s) : ST316,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sapience Enrolls First Patient in Phase 2 Study of ST316 for Colorectal Cancer
Details : ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9. It is being evaluated for the treatment of colorectal cancer.
Product Name : ST316
Product Type : Peptide
Upfront Cash : Not Applicable
October 01, 2024
Details:
Through the collaboration, Lisata will utilize MRD technology to detect ctDNA in a clinical trial evaluating CEND-1 (certepetide) combined with chemotherapy for the treatment of pancreatic cancer.
Lead Product(s): Certepetide,Panitumumab,Calcium Folinate
Therapeutic Area: Oncology Brand Name: CEND-1
Study Phase: Phase I/ Phase IIProduct Type: Peptide
Sponsor: Lisata Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 18, 2024
Lead Product(s) : Certepetide,Panitumumab,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Haystack Oncology and Lisata Therapeutics Start Collaboration to Use MRD™ Tech
Details : Through the collaboration, Lisata will utilize MRD technology to detect ctDNA in a clinical trial evaluating CEND-1 (certepetide) combined with chemotherapy for the treatment of pancreatic cancer.
Product Name : CEND-1
Product Type : Peptide
Upfront Cash : Undisclosed
July 18, 2024
Details:
Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Lead Product(s): Cetuximab,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Enlituo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
Details : Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Product Name : Enlituo
Product Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
Natrunix is an immunoglobulin cloned from healthy human donor which blocks IL-1α it is being investigated in combination with chemotherapy regimen for pancreatic cancer.
Lead Product(s): Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Natrunix
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Lead Product(s) : Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
XBiotech's Phase 1/2 Study Shows Promise for Pancreatic Cancer
Details : Natrunix is an immunoglobulin cloned from healthy human donor which blocks IL-1α it is being investigated in combination with chemotherapy regimen for pancreatic cancer.
Product Name : Natrunix
Product Type : Large molecule
Upfront Cash : Not Applicable
June 18, 2024
Details:
Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Onivyde
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Ipsen
Deal Size: $1,025.0 million Upfront Cash: $575.0 million
Deal Type: Acquisition March 27, 2024
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Ipsen
Deal Size : $1,025.0 million
Deal Type : Acquisition
Merrimack Receives $225 Million Milestone Payment from Ipsen
Details : Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.
Product Name : Onivyde
Product Type : Cytotoxic Drug
Upfront Cash : $575.0 million
March 27, 2024
Details:
Astellas' Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Brand Name: VYLOY
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Lead Product(s) : Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Details : Astellas' Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Product Name : VYLOY
Product Type : Large molecule
Upfront Cash : Not Applicable
March 26, 2024
Details:
AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Lead Product(s): ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Brand Name: ABTL0812
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: CTI Life Sciences
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 11, 2024
Lead Product(s) : ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
AbilityPharma Raises €7M to Advance Phase 2b ABTL0812 for Metastatic Pancreatic Cancer
Details : AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Product Name : ABTL0812
Product Type : Small molecule
Upfront Cash : Undisclosed
March 11, 2024
RLD : No
TE Code :
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Dosage Strength : EQ 3MG BASE/ML (EQ 3MG BASE/ML)
Approval Date : 1988-06-01
Application Number : 89352
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Dosage Strength : EQ 100MG BASE/10ML (EQ 10MG BASE/ML)
Approval Date : 2018-03-14
Application Number : 207241
RX/OTC/DISCN : RX
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : WELLCOVORIN
Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Dosage Strength : EQ 25MG BASE/5ML (EQ 5MG BASE/ML)
Approval Date : 1982-10-19
Application Number : 87439
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : WELLCOVORIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 100MG BASE/VIAL
Approval Date : 1989-01-23
Application Number : 89834
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : LEUCOVORIN CALCIUM PRESERVATIVE FREE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 200MG BASE/VIAL
Approval Date : 1995-05-23
Application Number : 40056
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : LEUCOVORIN CALCIUM PRESERVATIVE FREE
Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Dosage Strength : EQ 500MG BASE/50ML (EQ 10MG BASE/ML)
Approval Date : 2000-04-25
Application Number : 40347
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 200MG BASE/VIAL
Approval Date : 2023-07-19
Application Number : 216590
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Dosage Strength : EQ 500MG BASE/50ML (EQ 10MG BASE/ML)
Approval Date : 2018-11-23
Application Number : 210917
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2020-07-30
Application Number : 211132
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : LEUCOVORIN CALCIUM
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 1997-03-28
Application Number : 73099
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Related Excipient Companies
Excipients by Applications
Global Sales Information
Dosage Form :
Dosage Strength : Os Soluz 10 Vials Of 8 Ml
Price Per Pack (Euro) : 11.06
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 15 Ml
Price Per Pack (Euro) : 13.87
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : 10 Cpr 15 Mg
Price Per Pack (Euro) : 8
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 15 Mg
Price Per Pack (Euro) : 8.2
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : 6 Ampoules Im Ev 3 Mg + 6 Vials Solv 1 Ml ...
Price Per Pack (Euro) : 4.13
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : 6 Ampoules Im Ev 15 Mg + 6 Vials Solv 1 Ml...
Price Per Pack (Euro) : 7.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : 30 Cpr Riv 0.1 Mg + 0.5 Mg
Price Per Pack (Euro) : 4.79
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form :
Dosage Strength : To 6 Vials Im Ev + 6 Vials Solv 1.5 Ml
Price Per Pack (Euro) : 8.15
Published in :
Country : Italy
RX/OTC/DISCN : Class C
BIOHEALTH PHARMACEUTICALS Srl
Dosage Form :
Dosage Strength : 10 Cpr 15 Mg
Price Per Pack (Euro) : 6.3
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
BIOHEALTH PHARMACEUTICALS Srl
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 15 Mg
Price Per Pack (Euro) : 8.25
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
11 Feb 2025
Reply
31 Jan 2025
Reply
23 Jan 2025
Reply
09 Sep 2024
Reply
03 Sep 2024
Reply
26 Jan 2024
Reply
04 Aug 2023
Reply
28 Jul 2022
Reply
19 Jul 2022
REF. STANDARDS & IMPURITIES
CAS Number : 1492-18-8
Quantity Per Vial :
Price ($) : 240
Catalog Number : 1358004
Current Lot : R063P0
Previous Lot : K1K334 (31-MAR-2018)
NDC Code :
ABOUT THIS PAGE
12
PharmaCompass offers a list of Calcium Folinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Calcium Folinate manufacturer or Calcium Folinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcium Folinate manufacturer or Calcium Folinate supplier.
PharmaCompass also assists you with knowing the Calcium Folinate API Price utilized in the formulation of products. Calcium Folinate API Price is not always fixed or binding as the Calcium Folinate Price is obtained through a variety of data sources. The Calcium Folinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Calcium Folinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcium Folinate, including repackagers and relabelers. The FDA regulates Calcium Folinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcium Folinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcium Folinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcium Folinate supplier is an individual or a company that provides Calcium Folinate active pharmaceutical ingredient (API) or Calcium Folinate finished formulations upon request. The Calcium Folinate suppliers may include Calcium Folinate API manufacturers, exporters, distributors and traders.
click here to find a list of Calcium Folinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcium Folinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcium Folinate active pharmaceutical ingredient (API) in detail. Different forms of Calcium Folinate DMFs exist exist since differing nations have different regulations, such as Calcium Folinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcium Folinate DMF submitted to regulatory agencies in the US is known as a USDMF. Calcium Folinate USDMF includes data on Calcium Folinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcium Folinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcium Folinate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Calcium Folinate Drug Master File in Japan (Calcium Folinate JDMF) empowers Calcium Folinate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Calcium Folinate JDMF during the approval evaluation for pharmaceutical products. At the time of Calcium Folinate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Calcium Folinate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Calcium Folinate Drug Master File in Korea (Calcium Folinate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Calcium Folinate. The MFDS reviews the Calcium Folinate KDMF as part of the drug registration process and uses the information provided in the Calcium Folinate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Calcium Folinate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Calcium Folinate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Calcium Folinate suppliers with KDMF on PharmaCompass.
A Calcium Folinate CEP of the European Pharmacopoeia monograph is often referred to as a Calcium Folinate Certificate of Suitability (COS). The purpose of a Calcium Folinate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcium Folinate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcium Folinate to their clients by showing that a Calcium Folinate CEP has been issued for it. The manufacturer submits a Calcium Folinate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcium Folinate CEP holder for the record. Additionally, the data presented in the Calcium Folinate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcium Folinate DMF.
A Calcium Folinate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcium Folinate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcium Folinate suppliers with CEP (COS) on PharmaCompass.
A Calcium Folinate written confirmation (Calcium Folinate WC) is an official document issued by a regulatory agency to a Calcium Folinate manufacturer, verifying that the manufacturing facility of a Calcium Folinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Calcium Folinate APIs or Calcium Folinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Calcium Folinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Calcium Folinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcium Folinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Calcium Folinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Calcium Folinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Calcium Folinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcium Folinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Calcium Folinate suppliers with NDC on PharmaCompass.
Calcium Folinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcium Folinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcium Folinate GMP manufacturer or Calcium Folinate GMP API supplier for your needs.
A Calcium Folinate CoA (Certificate of Analysis) is a formal document that attests to Calcium Folinate's compliance with Calcium Folinate specifications and serves as a tool for batch-level quality control.
Calcium Folinate CoA mostly includes findings from lab analyses of a specific batch. For each Calcium Folinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcium Folinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcium Folinate EP), Calcium Folinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcium Folinate USP).